Keros Therapeutics, Inc. Operating Cash Flow
Keros Therapeutics, Inc. (KROS) reported Operating Cash Flow of -$23.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$20.42M.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.53M, a 102.19% decline year-over-year.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$27.29M.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $3.25M.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $107.50M.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$160.87M.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$124.51M.
- Keros Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$70.06M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$23.95M 10-Q · filed 2026-08-03 | -$51.24M derived: sum of 3 quarters · filed 2026-08-03 | -$47.99M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$3.53M 10-Q · filed 2026-05-14 | -$30.82M derived: sum of 2 quarters · filed 2026-05-14 | -$27.57M derived: sum of 3 quarters · filed 2026-05-14 | -$57.20M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$27.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$24.04M derived: sum of 2 quarters · filed 2026-03-04 | -$53.67M derived: sum of 3 quarters · filed 2026-08-03 | $107.50M 10-K · filed 2026-03-04 |
| 2025-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$26.37M derived: sum of 2 quarters · filed 2026-08-03 | $134.80M 10-Q · filed 2025-11-05 | $88.79M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$29.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $131.55M 10-Q · filed 2026-08-03 | $85.54M derived: sum of 3 quarters · filed 2026-08-03 | $55.04M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $161.17M 10-Q · filed 2026-05-14 | $115.16M derived: sum of 2 quarters · filed 2026-05-14 | $84.66M derived: sum of 3 quarters · filed 2026-05-14 | $44.86M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$46.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$76.51M derived: sum of 2 quarters · filed 2026-03-04 | -$116.31M derived: sum of 3 quarters · filed 2026-03-04 | -$160.87M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$30.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$70.30M derived: sum of 2 quarters · filed 2025-11-05 | -$114.86M 10-Q · filed 2025-11-05 | -$140.32M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$39.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$84.36M 10-Q · filed 2025-08-06 | -$109.82M derived: sum of 3 quarters · filed 2025-08-06 | -$143.80M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$44.56M 10-Q · filed 2025-05-06 | -$70.02M derived: sum of 2 quarters · filed 2025-05-06 | -$104.00M derived: sum of 3 quarters · filed 2025-05-06 | -$134.83M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$25.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$59.44M derived: sum of 2 quarters · filed 2025-02-26 | -$90.27M derived: sum of 3 quarters · filed 2025-02-26 | -$124.51M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$33.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$64.81M derived: sum of 2 quarters · filed 2024-11-06 | -$99.05M 10-Q · filed 2024-11-06 | -$120.49M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$30.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$65.07M 10-Q · filed 2024-08-07 | -$86.51M derived: sum of 3 quarters · filed 2025-02-26 | -$111.11M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$34.23M 10-Q · filed 2024-05-08 | -$55.68M derived: sum of 2 quarters · filed 2025-02-26 | -$80.28M derived: sum of 3 quarters · filed 2025-02-26 | -$102.87M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$21.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$46.05M derived: sum of 2 quarters · filed 2025-02-26 | -$68.64M derived: sum of 3 quarters · filed 2025-02-26 | -$70.06M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$24.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$47.19M derived: sum of 2 quarters · filed 2023-11-06 | -$48.62M 10-Q · filed 2023-11-06 | -$68.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$22.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$24.02M 10-Q · filed 2023-08-07 | -$43.58M derived: sum of 3 quarters · filed 2024-02-28 | -$58.02M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$1.43M 10-Q · filed 2023-05-04 | -$20.99M derived: sum of 2 quarters · filed 2024-02-28 | -$35.43M derived: sum of 3 quarters · filed 2024-02-28 | -$53.07M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$19.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$34.01M derived: sum of 2 quarters · filed 2024-02-28 | -$51.64M derived: sum of 3 quarters · filed 2024-02-28 | -$62.15M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$14.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$32.08M derived: sum of 2 quarters · filed 2022-11-03 | -$42.58M 10-Q · filed 2022-11-03 | -$50.57M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$17.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$28.14M 10-Q · filed 2022-08-04 | -$36.13M derived: sum of 3 quarters · filed 2022-08-04 | -$46.99M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$10.51M 10-Q · filed 2022-05-05 | -$18.50M derived: sum of 2 quarters · filed 2022-05-05 | -$29.35M derived: sum of 3 quarters · filed 2022-05-05 | -$39.28M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$7.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$18.85M derived: sum of 2 quarters · filed 2022-03-09 | -$28.77M derived: sum of 3 quarters · filed 2022-03-09 | -$36.89M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$10.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$20.78M derived: sum of 2 quarters · filed 2021-11-04 | -$28.90M 10-Q · filed 2021-11-04 | -$34.40M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$9.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$18.05M 10-Q · filed 2021-08-05 | -$23.55M derived: sum of 3 quarters · filed 2021-08-05 | -$26.50M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$8.12M 10-Q · filed 2021-05-06 | -$13.62M derived: sum of 2 quarters · filed 2021-05-06 | -$16.57M derived: sum of 3 quarters · filed 2021-05-06 | -$21.61M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$8.45M derived: sum of 2 quarters · filed 2021-03-25 | -$13.48M derived: sum of 3 quarters · filed 2021-03-25 | -$16.00M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$7.99M derived: sum of 2 quarters · filed 2020-11-10 | -$10.50M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$7.54M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$2.51M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |